GSK and Dong-A - Top 5 Emerging Market Deals

Who: GlaxoSmithKline
With: Dong-A Pharmaceuticals
Where: South Korea

Deal Size: $114 million

Details: In May GSK bought itself a 9.9 percent stake in Dong-A Pharmaceuticals, the number one pharma and OTC drugmaker in the fast-growing South Korean market. As part of the agreement, Dong-A will co-promote a roster of GSK primary-care products.

The Korean pharmaceutical market has been experience impressive pharma market growth (13.9% CAGR 2006-08), and was the 13th largest pharmaceutical market in the world in 2008. The market is expected to continue its double-digit growth spurt through to 2012. Prior to the deal, GSK was ranked fifth amount South Korean drugmakers with 2009 sales of $333.6 million. 

GSK and Dong-A - Top 5 Emerging Market Deals
Read more on

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.